Literature DB >> 2683316

Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-Guerin.

M Peuchmaur1, G Benoit, A Vieillefond, A Chevalier, G Lemaigre, E D Martin, A Jardin.   

Abstract

Immunohistochemical techniques were used to investigate leucocyte subpopulations in the bladders of patients with superficial transitional cell carcinoma treated with BCG Pasteur. Leucocyte subsets were enumerated with a panel of monoclonal antibodies which included CD3, CD4, CD8, TQ1, Leu7, CD15, HLA-DR, CD25, CD22. We demonstrated in the bladders of patients treated with BCG a particular lymphocyte population; the major subset was an inducer (CD4+, TQ1-) which was activated (CD25+, HLA-DR+) and associated with polymorphonuclear eosinophils. There was neither inducer of suppression nor major cytotoxic/suppressive subsets. CD8+ and NK cells could not be the primary mediators of BCG activity. These data supported the hypothesis of a helper T lymphocyte activity associated with lymphokine production and activation of effector killer cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2683316     DOI: 10.1007/bf00262987

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  12 in total

1.  Histopathology of BCG and thiotepa treated bladders.

Authors:  P Guinan; M Shaw; V Ray
Journal:  Urol Res       Date:  1986

2.  Mechanism of membrane damage mediated by human eosinophil cationic protein.

Authors:  J D Young; C G Peterson; P Venge; Z A Cohn
Journal:  Nature       Date:  1986 Jun 5-11       Impact factor: 49.962

3.  Immunohistochemical analysis of the human bladder.

Authors:  R A Gardiner; G J Seymour; M F Lavin; G M Strutton; E Gemmell; G Hazan
Journal:  Br J Urol       Date:  1986-02

4.  Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer.

Authors:  J M Lage; W C Bauer; D R Kelley; T L Ratliff; W J Catalona
Journal:  J Urol       Date:  1986-05       Impact factor: 7.450

Review 5.  BCG in management of superficial bladder cancer.

Authors:  P Guinan; R Crispen; M Rubenstein
Journal:  Urology       Date:  1987-12       Impact factor: 2.649

6.  Bacillus Calmette-Guerin immunotherapy for bladder cancer.

Authors:  D L Lamm
Journal:  J Urol       Date:  1985-07       Impact factor: 7.450

7.  Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin.

Authors:  D R Kelley; E O Haaff; M Becich; J Lage; W C Bauer; S M Dresner; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

8.  Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: a preliminary report.

Authors:  P A Merguerian; L Donahue; A T Cockett
Journal:  J Urol       Date:  1987-02       Impact factor: 7.450

9.  Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.

Authors:  E O Haaff; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

10.  [Treatment of superficial tumors and carcinomas in situ of the bladder by intravesical BCG therapy].

Authors:  A Steg; C Leleu; L Boccon-Gibod; B Debré
Journal:  Ann Urol (Paris)       Date:  1986
View more
  14 in total

1.  Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo.

Authors:  Y Luo; X Chen; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Y Luo; R Han; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2010-02-10       Impact factor: 4.330

3.  Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells.

Authors:  Y Luo; H Yamada; D P Evanoff; X Chen
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

Review 4.  Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer.

Authors:  J J Patard; D K Chopin; L Boccon-Gibod
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

Review 5.  Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Yi Luo; Matthew J Knudson
Journal:  Clin Dev Immunol       Date:  2010-09-01

6.  Study of recombinant human IFN-α-2b bacilli calmette-guerin activated killer cells and against bladder cancer cell in vitro.

Authors:  Xiaodong Fan; Ruifa Han
Journal:  Front Med China       Date:  2007-10

7.  Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells.

Authors:  X Chen; M A O'DONNELL; Y Luo
Journal:  Clin Exp Immunol       Date:  2007-05-21       Impact factor: 4.330

8.  Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.

Authors:  R Nadler; Y Luo; W Zhao; J K Ritchey; J C Austin; M B Cohen; M A O'Donnell; T L Ratliff
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

9.  On the mode of action of intravesical bacillus Calmette-Guérin: in vitro characterization of BCG-activated killer cells.

Authors:  A Böhle; A Thanhäuser; A J Ulmer; T Mattern; M Ernst; H D Flad; D Jocham
Journal:  Urol Res       Date:  1994

10.  Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG).

Authors:  Marcia R Saban; Cindy Simpson; Carole Davis; Gemma Wallis; Nicholas Knowlton; Mark Barton Frank; Michael Centola; Randle M Gallucci; Ricardo Saban
Journal:  BMC Immunol       Date:  2007-05-16       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.